Molecular and clinical aspects of embryotoxicity induced by acetylcholinesterase inhibitors
Tsiaoussis J., Hatzidaki E., Docea A. O., Nikolouzakis T. K., Petrakis D., Bury'kina T. I., Mamoulakis C., Makrigiannakis A., Tsatsakis A.
Toxicology
Vol.409, P. 137-143
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1016/j.tox.2018.07.018
Аннотация:
Acetylcholinesterase inhibitors are widely used for a variety of medical, agricultural and public health purposes. Consequently, exposure is highly possible during lifetime. However, their systematic use raises concerns for the potential impact on the fetus and newborn since these substances may affect angiogenesis, the neonatal and maternal intensive care, neuroimmune function and response, mammary growth/lactation via cholinergic/non-cholinergic central and peripheral neuroendocrine pathways. New methodologies, neuroscientific technologies and research studies are needed to harness existing knowledge along with the proper management, availability for new acetylcholinesterase inhibitors, with stable pharmacodynamics and clinical outcomes. © 2018 Elsevier B.V.
Ключевые слова:
Cholinesterase inhibitors; Endocrine disruptors; Fetus; Organophosphates; Parasympathomimetics; Toxicity
cholinesterase inhibitor; cholinesterase inhibitor; teratogenic agent; Article; clinical feature; embryotoxicity; endocrine disease; fetus development; fetus growth; homeostasis; human; lactation; liver toxicity; neurotoxicity; nonhuman; pregnancy; priority journal; animal; drug effect; mammalian embryo; physiology; Animals; Cholinesterase Inhibitors; Embryo, Mammalian; Humans; Teratogens
Язык текста: Английский
ISSN: 0300-483X
Tsiaoussis J.
Hatzidaki E.
Docea A. O.
Nikolouzakis T. K.
Petrakis D.
Bury'kina T. I. Tat`yana Ivanovna 1958-
Mamoulakis C.
Makrigiannakis A.
Tsatsakis A. Aristidis 1957-
Циаоуссис Й.
Хатзидаки Е.
Доcеа А. О.
Николоузакис Т. К.
Петракис Д.
Бурыкина Т. И. Татьяна Ивановна 1958-
Мамоулакис C.
Макригианнакис А.
Цацакис А. Аристидис 1957-
Molecular and clinical aspects of embryotoxicity induced by acetylcholinesterase inhibitors
Текст визуальный непосредственный
Toxicology
Elsevier Science Publisher B.V.
Vol.409 P. 137-143
2018
Статья
Cholinesterase inhibitors Endocrine disruptors Fetus Organophosphates Parasympathomimetics Toxicity
cholinesterase inhibitor cholinesterase inhibitor teratogenic agent Article clinical feature embryotoxicity endocrine disease fetus development fetus growth homeostasis human lactation liver toxicity neurotoxicity nonhuman pregnancy priority journal animal drug effect mammalian embryo physiology Animals Cholinesterase Inhibitors Embryo, Mammalian Humans Teratogens
Acetylcholinesterase inhibitors are widely used for a variety of medical, agricultural and public health purposes. Consequently, exposure is highly possible during lifetime. However, their systematic use raises concerns for the potential impact on the fetus and newborn since these substances may affect angiogenesis, the neonatal and maternal intensive care, neuroimmune function and response, mammary growth/lactation via cholinergic/non-cholinergic central and peripheral neuroendocrine pathways. New methodologies, neuroscientific technologies and research studies are needed to harness existing knowledge along with the proper management, availability for new acetylcholinesterase inhibitors, with stable pharmacodynamics and clinical outcomes. © 2018 Elsevier B.V.